Neftaly Protocols for CMV and EBV Prophylaxis

CMV Prophylaxis Protocol

1. Risk Stratification:

• High risk: CMV seronegative recipient with seropositive donor (D+/R−), or CMV seropositive recipients undergoing intense immunosuppression.
• Moderate/low risk: Seropositive recipient (R+) with a seropositive or seronegative donor.

2. Prophylactic Agents:

• First-line: Valganciclovir (oral) or Ganciclovir (IV).
• Alternatives: Valacyclovir (less common, usually in kidney transplants).

3. Duration:

• Typically 3–6 months post-transplant.
• Extended to 6 months or longer in lung and heart transplant patients or those with additional risk factors.

4. Dosing:

• Valganciclovir: 900 mg once daily, dose adjusted for renal function.
• Ganciclovir IV: 5 mg/kg every 12 hours initially (induction phase), then maintenance doses.

5. Monitoring:

• Weekly CMV PCR viral load monitoring during prophylaxis.
• Clinical monitoring for signs of CMV disease (fever, cytopenias, organ dysfunction).
• Adjust dose or consider preemptive therapy if viral load increases.

---

EBV Prophylaxis Protocol

1. Risk Stratification:

• EBV seronegative recipient with seropositive donor (D+/R−) is high risk for primary infection and PTLD (Post-transplant lymphoproliferative disorder).

2. Prophylactic Strategies:

• Immunosuppression minimization: Use the lowest effective immunosuppression.
• Antiviral therapy: Limited evidence supporting antivirals like ganciclovir or valganciclovir specifically for EBV; often not routinely used for prophylaxis but may be considered in high-risk cases.
• Preemptive monitoring: Routine EBV PCR viral load monitoring is standard.

3. Monitoring:

• Weekly to biweekly EBV PCR viral load screening in the first 3–6 months post-transplant.
• Increase frequency if viral loads rise.
• Early reduction of immunosuppression if viral load increases significantly.

4. Additional Measures:

• Consider Rituximab (anti-CD20) for preemptive therapy if viral load reaches high levels or clinical signs of PTLD develop.

---

If you want, I can help you draft specific dosing schedules or monitoring timelines for your exact transplant type or patient population. Would that help?Attach

Search

Study